Be careful, DNA has a long history of "next monday" it'll all be good and promising starts to the period. They may have lucked out on the win rate in July, who knows. I certainly wouldn't be annualising anything.
On the plus side, the vendor won't get his 25% on DSV EBITDA over USD16m unless, well, it makes USD16m+.
Massive current deficit even backing out the vendor loan. Let's hope they can sort that out, because with that vendor loan and the lack of rental payments hanging over it, DNA is uninvestable.
And thats assuming you don't care about how we got here and who is running this now, which one probably should.
Ann: FY22 Results Commentary, page-3
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DNA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.06M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 350000 | 2.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.0¢ | 70000 | 1 |
View Market Depth
| Last trade - 16.12pm 07/11/2024 (20 minute delay) ? |
| DNA (ASX) Chart |
Day chart unavailable